OSE Immunotherapeutics SA (EPA:OSE)

OSE Immunotherapeutics Balance Sheet

Financials in millions EUR. Fiscal year is January - December.

Assets

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	17.55	16.75	18.67	25.62	33.58
Short-Term Investments	14.12	49.05	10.82	-	9.85
Cash & Short-Term Investments	31.68	65.79	29.5	25.62	43.43
Cash Growth	-51.86%	123.06%	15.13%	-41.01%	12.06%
Accounts Receivable	0.31	4.14	0.98	0.4	-
Other Receivables	-	-	-	-	0.77
Total Trade Receivables	0.31	4.14	0.98	0.4	0.77
Other Current Assets	-	-	-	11.18	-
Total Current Assets	31.99	69.93	30.48	37.2	44.21
Net Property, Plant & Equipment	3.68	3.43	4.07	4.98	49.65
Other Intangible Assets	41.54	44.01	46.4	48.78	108.79
Long-Term Investments	1.46	6.4	0.91	0.64	0.94
Other Long-Term Assets	0.19	0.19	0.2	0.18	0.17
Total Assets	78.86	123.96	82.05	91.78	101.88

Liabilities

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	8.82	7.72	9.3	8.54	9.61
Accrued Expenses	1.2	2.04	0.35	0.82	1.05
Short-Term Debt	9.97	7.2	6.4	3.09	1.61
Current Portion of Leases	0.77	0.6	0.86	0.88	0.76
Other Current Liabilities	3.22	2.67	1.89	2.94	3.74
Total Current Liabilities	24.9	20.22	18.8	16.27	16.76
Long-Term Debt	21.83	35.66	35.51	37.23	30.8
Long-Term Leases	2.81	2.68	3.03	3.59	3.97
Other Long-Term Liabilities	1.56	1.59	1.74	2.04	2.46
Total Long-Term Liabilities	26.2	39.93	40.28	42.86	37.22
Total Liabilities	51.1	60.15	59.08	59.12	53.99

Shareholders' Equity

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	4.49	4.39	4.33	3.71	3.71
Treasury Stock	-0.34	-0.45	-0.41	-0.55	-0.16
Additional Paid-in Capital	77.71	77.74	76.64	65.61	65.61
Retained Earnings	-54.11	-17.87	-57.59	-36.11	-21.26
Shareholders' Equity	27.76	63.81	22.98	32.66	47.89
Total Liabilities & Equity	78.86	123.96	82.05	91.78	101.88

Additional Metrics

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	35.38	46.13	45.8	44.79	37.13
Net Cash (Debt)	-3.7	19.66	-16.31	-19.17	6.3
Net Cash Growth	-	-	-	-	-67.26%
Net Cash Per Share	-0.17	0.90	-0.83	-1.03	0.35
Book Value	27.76	63.81	22.98	32.66	47.89
Book Value Per Share	1.25	2.93	1.17	1.76	2.64
Tangible Book Value	-13.79	19.8	-23.43	-16.13	-60.9
Tangible Book Value Per Share	-0.62	0.91	-1.20	-0.87	-3.35

Data Source: Fiscal.ai Last updated: May 1, 2026

Financial data is provided by Fiscal.ai and updates within minutes after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Jul 31, 2026

Data Sources Report a data error